Business
Hemostemix Announces the Bread Contract with the Department of Foreign Affairs, Trade & Development Canada
Calgary, Alberta--(Newsfile Corp. - January 22, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTX...
About this update from Hemostemix Inc
[{"type":"text","content":"Hemostemix Announces the Bread Contract with the Department of Foreign Affairs, Trade & Development CanadaCalgary, Alberta--(Newsfile Corp. - January 22, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXD) (\"Hemostemix\" or the \"Company\") is pleased to announce it has signed the Building Relationships Entrepreneurs & Dealmakers (BREAD) contract with the Department of Foreign Affairs, Trade and Development. An initiative to assist high-potential, biotech focused Canadian Small and Medium Enterprise (SMEs), the program is designed to accelerate the growth of Hemostemix and other Canadian biotechnology companies.\"We are actively working with the Trade Commissioner Service of CANADA in the USA, Japan and South Korea to source qualified partners to go to market with,\" stated Thomas Smeenk, CEO. \"The BREAD agreement marks our Company's starting point to out-license ACP-01, and it generates our sponsorship into BioCom.\" ABOUT THE TRADE COMMISSIONER SERVICE OF CANADAThe Trade Commissioner Service (TCS) plays an active role in helping Canadian companies achieve their goals of growth into international markets. Its services focus on helping companies prepare for international markets, assessing market potential, finding qualified contacts and partners and resolving problems.ABOUT HEMOSTEMIX Hemostemix is a publicly traded autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat over 300 patients, and it is the subject of a randomized, placebo-controlled, double blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation.On October 21, 2019, the Company announced the results from its Phase II CLI trial abstract presentation entitled \"Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Follow-up\", which noted healing of ulcers and resolution of ischemic rest pain occurred in 83% of patients, with outcomes maintained for up to 4.5 years.The Company owns 91 patents across fi...